8-K: Zymeworks Reports Q1 2024 Financial Results and Provides Corporate Update

Zymeworks announced its first quarter 2024 financial results, highlighting a cash runway into the second half of 2027 and progress in its clinical programs.

Summary

• Zymeworks reported a net loss of $31.7 million for the first quarter of 2024, compared to a $24.4 million loss in the same period of 2023.
• Revenue for the quarter was $10.0 million, a decrease from $35.6 million in the first quarter of 2023, primarily due to the transfer of zanidatamab clinical trial responsibilities to Jazz Pharmaceuticals.
• Research and development expenses decreased to $32.0 million from $45.9 million year-over-year, also due to the transfer of zanidatamab program costs.
• The company's cash resources totaled $420.5 million as of March 31, 2024, which, combined with anticipated regulatory milestone payments, is expected to fund operations into the second half of 2027.
• Zymeworks is advancing its pipeline with two planned IND submissions in 2024 for ZW191 and ZW171.
• Jazz Pharmaceuticals, Zymeworks' partner, completed the rolling BLA submission to the FDA for zanidatamab in biliary tract cancer and plans to initiate a Phase 3 trial for breast cancer in the second half of 2024.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the strong cash position and progress in clinical programs, but tempered by the decrease in revenue and increased net loss. The company's cash runway is a positive sign, but the financial results show a decline in revenue and an increase in net loss.

Positives

• The company has a strong cash position of $420.5 million, providing a cash runway into the second half of 2027.
• The BLA submission for zanidatamab in biliary tract cancer has been completed by Jazz Pharmaceuticals.
• The planned Phase 3 trial for zanidatamab in breast cancer represents a significant step forward in its clinical development.
• Zymeworks is advancing its own pipeline with two IND submissions planned for 2024.
• The company presented five abstracts at the AACR annual meeting, showcasing its R&D progress.
• The company is seeing increased interest income due to higher rates of return on cash, cash equivalents and marketable securities.

Negatives

• Revenue decreased significantly to $10.0 million in Q1 2024 from $35.6 million in Q1 2023.
• The net loss increased to $31.7 million in Q1 2024 from $24.4 million in Q1 2023.
• The decrease in revenue and increase in net loss are primarily due to the transfer of zanidatamab clinical trial responsibilities to Jazz Pharmaceuticals.

Risks

• The company's future success is dependent on the success of its clinical trials and regulatory approvals.
• The company may not achieve milestones or receive additional payments under its collaborations.
• Regulatory agencies may impose additional requirements or delay the initiation of clinical trials.
• Clinical trials may not demonstrate the safety and efficacy of the company's product candidates.
• The company's assumptions and estimates regarding its financial condition and cash runway may be incorrect.
• The company may be unable to maintain or enter into new partnerships or strategic collaborations.

Future Outlook

Zymeworks expects its current cash resources, combined with anticipated regulatory milestone payments, to fund operations into the second half of 2027. The company also anticipates multiple Phase 1 trials in the coming 24 months and plans to submit two INDs in 2024.

Management Comments

• Kenneth Galbraith, Chair and Chief Executive Officer of Zymeworks, stated that the company is pleased to have presented five poster presentations at AACR, showcasing Zymeworks' ability to apply key insights from its proprietary technology.
• Mr. Galbraith also noted that the company's anticipated cash runway remains on track to support the development of its 5 by 5 product pipeline into the second half of 2027.
• Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks, stated that the company's R&D efforts are focused on attractive targets, with the ability to use its proprietary technology to develop next generation candidates.

Industry Context

This announcement reflects the ongoing development of novel biotherapeutics in the oncology space, with a focus on antibody-drug conjugates and multispecific antibodies. The collaboration with Jazz Pharmaceuticals highlights the trend of partnerships in the biotech industry to advance clinical programs and share development costs. The focus on HER2-expressing cancers aligns with the industry's efforts to target specific cancer biomarkers.

Comparison to Industry Standards

• Zymeworks' cash runway into the second half of 2027 is a positive sign, indicating financial stability compared to many other clinical-stage biotech companies that often face near-term funding challenges.
• The decrease in revenue due to the transfer of clinical trial responsibilities to Jazz is a common occurrence in biotech partnerships, where companies often share development costs and responsibilities.
• The progress of zanidatamab, with a completed BLA submission and a planned Phase 3 trial, is comparable to other companies developing targeted therapies for cancer.
• The focus on both antibody-drug conjugates and multispecific antibodies positions Zymeworks as a company with a diverse technology platform, similar to other leading biotech firms in the oncology space.

Management Changes

Stakeholder Impact

• Shareholders may be concerned about the decrease in revenue and increased net loss, but reassured by the strong cash position and extended cash runway.
• Employees may be impacted by the decrease in headcount, but the company's focus on R&D and clinical development suggests continued investment in its pipeline.
• Customers and partners may be encouraged by the progress of zanidatamab and the company's pipeline, indicating potential future products and collaborations.
• Creditors may be reassured by the company's strong cash position and extended cash runway.

Next Steps

• Jazz Pharmaceuticals will initiate a Phase 3 clinical trial for zanidatamab in breast cancer in the second half of 2024.
• Zymeworks plans to submit two IND and foreign equivalent submissions for ZW191 and ZW171 in 2024.
• Zymeworks will continue to present preclinical data for its early-stage pipeline throughout 2024.
• Jazz Pharmaceuticals plans to submit a marketing authorization application (MAA) to the European Medicines Agency (EMA) for zanidatamab in BTC.

Key Dates

Keywords

Zymeworks, zanidatamab, biotherapeutics, clinical trials, FDA, Jazz Pharmaceuticals, biliary tract cancer, breast cancer, IND, antibody-drug conjugate, multispecific antibody, cash runway, financial results